Regeneron Pharmaceuticals (NASDAQ:REGN) Trading Down 7.8% - Here's What Happened

Key Points

• Stock fell ~7.8% intraday — shares dropped after reported weakness in total EYLEA U.S. sales and concern about rising competition in the retina market, prompting a selloff despite strong uptake of EYLEA HD and Dupixent demand.
• Q1 beat but mixed investor reaction — Regeneron posted non‑GAAP EPS of $9.47 and $3.61B in revenue (up 19%), announced up to $3B in buybacks and a higher dividend, yet analysts' views and near‑term product/campaign risks left sentiment uneven (consensus: Moderate Buy).

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report)'s stock price traded down 7.8% during mid-day trading on Wednesday . The company traded as low as $676.71 and last traded at $674.4270. 885,633 shares were traded during mid-day trading, an increase of 21% from the average session volume of 734,401 shares. The stock had previously closed at $731.77.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q1 beat on both EPS and revenue: Regeneron reported non‑GAAP EPS of $9.47 and revenue of ~$3.6B, topping estimates and showing 19% revenue growth — a strong near‑term financial print. Regeneron beats quarterly results estimates on strong Dupixent demand (Reuters)
• Positive Sentiment: Dupixent and EYLEA HD momentum: Dupixent demand remains a key growth driver (Sanofi‑reported Dupixent sales +33%); EYLEA HD U.S. adoption rose sharply (EYLEA HD U.S. net sales +52%), supporting medium‑term growth prospects. Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Zacks)
• Positive Sentiment: $3B buyback announced: Management authorized up to $3 billion in share repurchases, which supports EPS and signals management confidence. Regeneron shares slide despite Q1 beat (ProactiveInvestors)
• Neutral Sentiment: Pipeline milestones could be value drivers but are not immediate: Progress in the C5 complement program (PNH enrollment complete) and positive Phase III data for cemdisiran in myasthenia gravis set up potential multi‑indication launches as early as Q4 2026 — longer‑term upside if approvals materialize. Regeneron’s C5 Milestones And Autoimmune Bets Shape Future Valuation (Yahoo)
• Neutral Sentiment: Full earnings call details and management commentary available for color on margins, IPR&D impacts and product cadence — useful for modeling but not a single catalyst. Regeneron Q1 2026 Earnings Call Transcript (Seeking Alpha)
• Negative Sentiment: EYLEA U.S. sales disappointed vs. Street expectations: Despite HD uptake, total EYLEA U.S. net sales declined ~10% and reported U.S. high‑dose sales missed expectations, fueling the intraday selloff. Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug (Yahoo)
• Negative Sentiment: Rising competition and upcoming biosimilars/new entrants: Analysts flag intensified competition in the retina market and several competitors with data or launches coming later this year, which could pressure EYLEA revenue and valuation going forward. Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock. (Yahoo)

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Wall Street Zen downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, April 11th. Cantor Fitzgerald reiterated an "overweight" rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. JPMorgan Chase & Co. lifted their price target on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an "overweight" rating in a report on Monday, February 2nd. Weiss Ratings reiterated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Finally, Evercore lifted their price target on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an "outperform" rating in a report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $825.35.

Regeneron Pharmaceuticals Trading Down 6.6%

The company has a market cap of $72.25 billion, a P/E ratio of 16.37, a PEG ratio of 1.71 and a beta of 0.40. The business has a fifty day moving average price of $760.43 and a 200-day moving average price of $735.71. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $9.10 by $0.37. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company had revenue of $3.61 billion during the quarter, compared to analysts' expectations of $3.45 billion. During the same quarter in the previous year, the company posted $8.22 earnings per share. The business's revenue was up 19.0% on a year-over-year basis. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.98 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were issued a dividend of $0.94 per share. This is a boost from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 9.05%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, SVP Jason Pitofsky sold 2,036 shares of the business's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the sale, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business's stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares of the company's stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,774 shares of company stock worth $2,942,738 over the last quarter. Company insiders own 7.02% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. WPG Advisers LLC grew its stake in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 25 shares in the last quarter. SHP Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $26,000. Salomon & Ludwin LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $27,000. Titan Wealth CI Ltd acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $29,000. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. Institutional investors own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.